

Gut Microbiome, Probiotics and Bone: An Updated Mini Review

Myriam Abboud, Dimitrios Papandreou*

Department of Health, CNHS, Zayed University, Dubai, UAE

Abstract

Citation: Abboud M, Papandreou D. Gut Microbiome, Probiotics and Bone: An Updated Mini Review. Open Access Maced J Med Sci. 2019 Feb 15; 7(3):478-481. <https://doi.org/10.3889/oamjms.2019.047>

Keywords: Microbiome; Probiotics; Bone

***Correspondence:** Dimitrios Papandreou. Department of Health, CNHS, Zayed University, Dubai, UAE. E-mail: Dimitrios.papandreou@zu.ac.ae

Received: 27-Nov-2018; **Revised:** 25-Dec-2018; **Accepted:** 12-Jan-2019; **Online first:** 11-Feb-2019

Copyright: © 2019 Myriam Abboud, Dimitrios Papandreou. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

Funding: This research did not receive any financial support

Competing Interests: The authors have declared that no competing interests exist

The gut microbiome is now considered as a large organ that has a direct effect on gastrointestinal tract, immune and endocrine system. There is no evidence that gut microbiota regulates the immune system and is responsible for bone formation and destruction. Probiotics have been shown through the gastrointestinal tract to have a positive effect on the management of the healthy bone. This article discusses the latest data available from PubMed and Scopus databases regarding gut microbiome, probiotics and bone briefly.

Introduction

Gut microbiome (GM) is the largest one that includes trillions of bacteria, fungi and viruses that live in the intestinal tract. These *bacteria* have been found to modulate immune responses that are associated with many diseases such as Crohn's, irritable bowel syndrome, celiac, cardiovascular, and rheumatic [1]. GM is a major regulator of bone mineral density via the effects of the immune system [2], [3].

It has been reported by several clinical trials the association of low intestinal bacteria and decreased bone mineral density [4]. There is no convincing evidence of the role of GM in the development of bone formation and destruction [4]. Very recently the importance of microbiome health has become now clear; many consider it as a new large organ, while specific strains have been identified to affect immune cells [5].

Review of Text

Osteoporosis is a major public health burden in our ageing population [6]. Bone undergoes turnover continuously, and the immune system is regulating this process since 1980 [7]. This chronic progressive bone disease is mainly due to the natural cessation of endogenous estrogen marked by the onset of menopause and characterised by decreased bone mineral density (BMD) and negative changes in bone microarchitecture [8]. Estrogen cessation gives rise to two stages of bone loss: an early rapid loss of trabecular and cortical bone due to increased osteoclast activity and decreased osteoclast apoptosis, and a second slower prolonged loss due to decreased osteoblast activity [9]. This notable imbalance between bone formation and bone resorption increases the risk of fractures among postmenopausal women [10], [11]. Although estrogen therapy (ET) was shown effective in the prevention and treatment of estrogen-deficient osteoporosis in

postmenopausal women, its use remains controversial due to its association with increased risk of breast, endometrium and ovaries cancer [12].

Recently, alternative and complementary therapies such as dietary supplements have become the preferred prophylactic treatment of clinicians and patients in the prevention and management of osteopenia [13]. Meta-analyses have shown that daily intake of 1200 mg Calcium (Ca) and 20–25 mg vitamin D (D) can reduce total- and hip-fracture risk by 15% and 30%, respectively, [14], hence, it seems that Ca and D supplementation alone is not sufficient to fully prevent the menopausal bone loss.

In the past decade, a growing body of evidence suggests that probiotics may have favourable effects on bone health. Probiotics are living microorganisms that could influence the GM composition and exert positive effects that have been attributed to several complex mechanisms, including enhanced mineral absorption, beneficial anti-inflammatory pathways [15] and many more. Probiotic strains differ significantly in genotype and phenotype, and they may show different metabolic functions, particularly with regards to immune function [16].

In earlier reports, various strains of *Lactobacillus* and *Bifidobacterium* were shown to prevent and even restore bone loss related to estrogen deficiency [17], they were also shown to cause a 45% increase in femoral and vertebral trabecular bone volume fraction in mice [18]. More recently, a randomized, double-blind, placebo-controlled study [19] revealed that multispecies probiotic supplementation (7 specific strains: *Lactobacillus casei*, *Bifidobacterium longum*, *Lactobacillus acidophilus*, *Lactobacillus rhamnosus*, *Lactobacillus bulgaricus*, *Bifidobacterium breve* and *Streptococcus thermophiles*) among postmenopausal osteopenic women diminished bone resorption through significant effects on serum concentrations of bone biomarkers, such as serum bone-specific alkaline phosphatase (s-BALP) and serum C-terminal telopeptide of type I collagen (CTX). Decreased serum levels of BALP, the marker of bone turnover and CTX-produced by osteoclasts during the bone resorption process- compared to the placebo group, suggest a protective effect of this multispecies probiotic against bone resorption. These results are consistent with earlier studies using *Bifidobacterium subtilis* (CH201) [20], *Bifidobacterium longum* [21] and *Lactobacillus reuteri* [22].

The beneficial effects of probiotics on nutrients absorption were highlighted in several recent reports. Various strains of *Lactobacillus* and *Bifidobacteria* were shown to influence the pH of the gut and the metabolism of bile acids [23], important factors in the control of nutrients absorption, especially calcium. *Lactobacillus helveticus* fermented milk exhibited an acute positive effect on calcium metabolism. Thus, in

addition to the well-established benefits of calcium and vitamin D content of milk, it is possible that some types of probiotics may aid in the breakdown of proteins contained in milk to biologically active peptides [24]. Furthermore, elevated concentration of *Lactobacillus reuteri* and *Bifidobacterium longum* in the gut may be involved in promoting mineral (calcium, magnesium, and phosphate) absorption resulting in an increased BMD. Probiotics were also shown to play an essential role in the synthesis of vitamin B and vitamin K, which are critical for the regulation of bone health [25].

On another note, various strains of probiotics were shown to affect bone health via the production of short-chain fatty acids (SCFA). SCFA are byproducts produced by the microbiota during fermentation of dietary fibre and were reported to have direct effects on osteoclasts and osteoblasts. For example, butyrate is an SCFA known to reduce osteoclastogenesis by suppressing the receptor activator for nuclear factor κ B ligand signalling pathway [26]. More recently, SCFA were shown to have indirect effects on endocrine factors such as peptide YY and glucagon-like peptide 1. Peptide YY is a gastrointestinal hormone secreted from the endocrine L cells and is negatively associated with the total body and hip BMD in premenopausal women [27]. Glucagon-like peptide 1, an amino acid hormone that is also secreted from the endocrine L cells, has been shown to act as a regulator of bone metabolism by altering the balance between osteoblast and adipocyte differentiation from bone mesenchymal stem cells [28].

When it comes to the immune-modulatory properties, probiotic administration was shown to reduce the expression of several pro-inflammatory and osteolytic cytokines such as Tumor Necrosis Factor- α (TNF- α) and Interleukin-1b (IL-1b) [29]. *Lactobacillus reuteri*, *Lactobacillus rhamnosus* and *Lactobacillus paracasei* [30] were shown to decrease osteoclastogenesis and bone resorption significantly. *Lactobacillus reuteri* enhanced the suppression of pro-inflammatory cytokines TNF-mediated bone resorption in mice [19] and enhanced the reduction of the percentage of CD4C T cells in bone marrow [22]. The treatment was able to improve bone health in healthy male mice [19]. Similarly, decreased TNF- α and IL-1b, along with increased anti-inflammatory cytokine IL-10 also resulted from oral administration of *Saccharomyces cerevisiae* [31].

One of the recent applications of probiotics is the incorporation of *Bacillus spp.* in birds' feeds to promote growth, as an alternative to the harmful antibiotic growth promoters (AGP). Several studies show that certain strains of *Bacillus subtilis* also promote the growth of chickens to a greater extent than AGP [32].

On the other hand, it is important to note that, in contrast with the reported benefits of probiotics on bone health, a recent study [6]

showed that dietary enrichment with powdered whole grape and probiotics (composed of equal parts *Bifidobacterium bifidum*, *B. breve*, *Lactobacillus casei*, *L. plantarum*, and *L. bulgaricus*) exerted either no effect on bone microarchitecture in a mouse model of age-related osteoporosis. However, this negative effect was attributed to possible differences in probiotic strains, the small sample size and the duration of the supplementation.

Conclusions

Current research efforts, although varied, mostly indicate favourable effects of probiotics on bone metabolism. Therefore, long-term investigations with different strains of probiotics are needed to dissect the mechanisms and effects on bone formation and resorption, especially in humans.

This relationship is a promising area of investigation, which potential outcomes could lead to physicians directing their therapeutic efforts to probiotics, among dietary supplements, for most effective treatments for bone-related ailments.

Future directions are focused now on the major role of the gut microbiome in rheumatic disease, and a lot of interest is growing in the gut microbiome manipulation as a therapeutic tool for bone diseases. Preclinical models may also be a future promise for the treatment of bone disease.

References

- Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? *Nat Rev Gastroenterol Hepatol*. 2017; 14(10):573-584. <https://doi.org/10.1038/nrgastro.2017.88>
- Stotzer PO, Johansson C, Mellström D, Lindstedt G, Kilander AF. Bone mineral density in patients with small intestinal bacterial overgrowth. *Hepatology*. 2003; 50(53):1415-8. PMID:14571751
- Park H. The role of small intestinal bacterial overgrowth in the pathophysiology of irritable bowel syndrome. *J Neurogastroenterol Motil*. 2010; 16(1):3-4. <https://doi.org/10.5056/jnm.2010.16.1.3> PMID:20535319 PMID:PMC2879822
- Ibanez L, Rouleau M, Wakkach A, Wakkach CB. Gut Microbiome and bone. *Joint Bone Spine*. 2018. pii: S1297-319X(18)30061-7.
- Hsu E, Pacifici R. From Osteoimmunology to Osteomicrobiology: How the Microbiota and the Immune System Regulate Bone. *Calcif Tissue Int*. 2018; 102(5):512-521. <https://doi.org/10.1007/s00223-017-0321-0> PMID:29018933
- Blanton, C. Bone Response to Dietary Co-Enrichment with Powdered Whole Grape and Probiotics. *Nutrients*. 2018; 10(2). <https://doi.org/10.3390/nu10020146>
- Pacifici R, Rifas L, Teitelbaum S, Slatopolsky E, McCracken R, Bergfeld M, Lee W, Avioli LV, Peck WA. Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. *Proc Natl Acad Sci U S A*. 1987; 84(13):4616-20. <https://doi.org/10.1073/pnas.84.13.4616> PMID:3496597 PMID:PMC305141
- Yan J, Charles JF. Gut microbiome and bone: to build, destroy, or both? *Current osteoporosis reports*. 2017; 15(4):376-84. <https://doi.org/10.1007/s11914-017-0382-z> PMID:28620867 PMID:PMC5538387
- Collins FL, Rios-Arce ND, Schepper JD, Parameswaran N, McCabe LR. The Potential of Probiotics as a Therapy for Osteoporosis. *Microbiology spectrum*. 2017; 5(4). <https://doi.org/10.1128/microbiolspec.BAD-0015-2016>
- Bonnick SL. Osteoporosis in men and women. *Clinical cornerstone*. 2006; 8(1):28-39. [https://doi.org/10.1016/S1098-3597\(06\)80063-3](https://doi.org/10.1016/S1098-3597(06)80063-3)
- Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *Cmaj*. 2010; 182(17):1864-73. <https://doi.org/10.1503/cmaj.100771> PMID:20940232 PMID:PMC2988535
- Bowring CE, Francis RM. National Osteoporosis Society's Position statement on hormone replacement therapy in the prevention and treatment of osteoporosis. *Menopause International*. 2011; 17(2):63-5. <https://doi.org/10.1258/mi.2011.011012> PMID:21693502
- Lambert MN, Thybo CB, Lykkeboe S, Rasmussen LM, Frette X, Christensen LP, Jeppesen PB. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial. *The American journal of clinical nutrition*. 2017; 106(3):909-20. <https://doi.org/10.3945/ajcn.117.153353>
- Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, Liu S, Looker AC, Wallace TC, Wang DD. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. *Osteoporosis International*. 2016; 27(1):367-76. <https://doi.org/10.1007/s00198-015-3386-5> PMID:26510847 PMID:PMC4715837
- Chen YC, Greenbaum J, Shen H, Deng HW. Association between gut microbiota and bone health: potential mechanisms and prospective. *The Journal of Clinical Endocrinology & Metabolism*. 2017; 102(10):3635-46. <https://doi.org/10.1210/jc.2017-00513> PMID:28973392 PMID:PMC5630250
- Dong H, Rowland I, Yaqoob P. Comparative effects of six probiotic strains on immune function in vitro. *British Journal of Nutrition*. 2012; 108(3):459-70. <https://doi.org/10.1017/S0007114511005824> PMID:22054064
- Parvaneh K, Ebrahimi M, Sabran MR, Karimi G, Hwei AN, Abdul-Majeed S, Ahmad Z, Ibrahim Z, Jamaluddin R. Probiotics (*Bifidobacterium longum*) increase bone mass density and upregulate Sparc and Bmp-2 genes in rats with bone loss resulting from ovariectomy. *BioMed research international*. 2015; 2015.
- Scholz-Ahrens KE, Adolphi B, Rochat F, Barclay DV, de Vrese M, Ac, il Y, Schrezenmeir J. Effects of probiotics, prebiotics, and synbiotics on mineral metabolism in ovariectomized rats—impact of bacterial mass, intestinal absorptive area and reduction of bone turn-over. *NFS J*. 2016; 3:41–5. <https://doi.org/10.1016/j.nfs.2016.03.001>
- McCabe LR, Irwin R, Schaefer L, Britton RA: Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. *Journal of Cell Physiology*. 2013; 228:1793–1798. <https://doi.org/10.1002/jcp.24340> PMID:23389860 PMID:PMC4091780
- Jafarnejad S, Djafarian K, Fazeli MR, Yekaninejad MS, Rostamian A, Keshavarz SA. Effects of a multispecies probiotic supplement on bone health in osteopenic postmenopausal women: a randomized, double-blind, controlled trial. *Journal of the American College of Nutrition*. 2017; 36(7):497-506.

- <https://doi.org/10.1080/07315724.2017.1318724> PMID:28628374
21. Messoria MR, Oliveira LF, Foureaux RC, Taba M Jr, Zangerônimo MG, Furlaneto FA, Pereira LJ. Probiotic therapy reduces periodontal tissue destruction and improves the intestinal morphology in rats with ligature-induced periodontitis. *J Periodontol*. 2013; 84(12):1818-26. <https://doi.org/10.1902/jop.2013.120644> PMID:23327675
22. Britton RA, Irwin R, Quach D, Schaefer L, Zhang J, Lee T, Parameswaran N, McCabe LR. Probiotic *L. reuteri* treatment prevents bone loss in a menopausal ovariectomized mouse model. *Journal of Cell Physiology*. 2014; 229:1822–1830. <https://doi.org/10.1002/jcp.24636> PMID:24677054 PMCid:PMC4129456
23. Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: gut microbiota: the neglected endocrine organ. *Molecular Endocrinol*. 2014; 28(8):1221–1238. <https://doi.org/10.1210/me.2014-1108> PMID:24892638 PMCid:PMC5414803
24. Mohanty DP, Mohapatra S, Misra S, Sahu PS. Milk derived bioactive peptides and their impact on human health: a review. *Saudi Journal of Biological Science*. 2016; 23(5):577–583. <https://doi.org/10.1016/j.sjbs.2015.06.005> PMID:27579006 PMCid:PMC4992109
25. Villa JK, Diaz MA, Pizziolo VR, Martino HS. Effect of vitamin K in bone metabolism and vascular calcification: a review of mechanisms of action and evidences. *Critical Reviews in Food Science and Nutrition*. 2017; 57(18):3959-3970. <https://doi.org/10.1080/10408398.2016.1211616> PMID:27437760
26. Rahman MM, Kukita A, Kukita T, Shobuie T, Nakamura T, Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. *Blood*. 2003; 101(9):3451–3459. <https://doi.org/10.1182/blood-2002-08-2622> PMID:12511413
27. Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. *Circulation Research*. 2017; 120(7):1183–1196. <https://doi.org/10.1161/CIRCRESAHA.117.309715> PMID:28360349 PMCid:PMC5390330
28. Luo G, Liu H, Lu H. Glucagon-like peptide-1 (GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? *British Journal of Clinical Pharmacology*. 2016; 81(1):78–88. <https://doi.org/10.1111/bcp.12777> PMID:27099876 PMCid:PMC4693579
29. Mbalaviele G, Novack DV, Schett G, Teitelbaum SL. Inflammatory osteolysis: a conspiracy against bone. *J Clin Invest*. 2017; 127(6):2030-2039. <https://doi.org/10.1172/JCI93356> PMID:28569732 PMCid:PMC5451216
30. Li JY, Chassaing B, Tyagi AM, Vaccaro C, Luo T, Adams J, Darby TM, Weitzmann MN, Mülle JG, Gewirtz AT, Jones RM, Pacifici R. Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. *Journal of Clinical Investigations*. 2016; 126(6):2049–2063. <https://doi.org/10.1172/JCI86062> PMID:27111232 PMCid:PMC4887186
31. Garcia VG, Knoll LR, Longo M, Novaes VC, Assem NZ, Ervolino E, de Toledo BE, Theodoro LH. Effect of the probiotic *Saccharomyces cerevisiae* on ligature-induced periodontitis in rats. *Journal of Periodontal Research*. 2016; 51:26–37. <https://doi.org/10.1111/jre.12274> PMID:25918871
32. Grant AQ, Gay CG, Lillehoj HS. *Bacillus* spp. as direct-fed microbial antibiotic alternatives to enhance growth, immunity, and gut health in poultry. *Avian Pathology*. 2018; 47(4):339-51. <https://doi.org/10.1080/03079457.2018.1464117> PMID:29635926